✦ LIBER ✦

Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature

✍ Scribed by Dalgleish, Angus; Featherstone, Peter; Vlassov, Viatcheslav; Rogosnitzky, Moshe

Book ID: 121570722
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 346 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-014-0063-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Presentation of prostatic adenocarcinoma

Presentation of prostatic adenocarcinoma with cervical lymphadenopathy: Two case reports and review of the literature

✍ S.V. Chitale; L. Harry; C.G.C. Gaches; R.Y. Ball 📂 Article 📅 2001 🏛 SAGE Publications 🌐 English ⚖ 66 KB

Expression of the chemokine receptor CCR

Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: Report of a case, review of the literature, and analysis of chemokine receptor expression

✍ Gustavo A. Heresi; Jingcheng Wang; Russell Taichman; Julio A. Chirinos; Jacinto 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 351 KB

CD20-negative DLBCL transformation after

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature

✍ T. Álvaro-Naranjo; J. Jaén-Martínez; J. Gumá-Padró; R. Bosch-Príncep; M. T. Salv 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 181 KB

Loss of CD20 expression in relapsed diff

Loss of CD20 expression in relapsed diffuse large B cell lymphoma after rituximab therapy: a case report and review of the literature

✍ Yao Jiang,Yingchao Zhao,Xiaorong Dong… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 379 KB

Rituximab for chronic recurring thrombot

Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

✍ Roslyn Yomtovian; Waldemar Niklinski; Bernard Silver; Ravindra Sarode; Han-Mou T 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB

CD8+ cutaneous T-cell lymphoma successfu

CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: A case report and review of the literature

✍ Srivalli Gopaluni; Raiza Perzova; Lynn Abbott; Ramsey Farah; Anthony Shrimpton; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

## Abstract CD8+ cutaneous T‐cell lymphoma (CTCL) is a relatively rare subset of the non‐Hodgkins lymphomas. Bexarotene has been FDA‐approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report